Newer antihistaminic agents.
Two new antihistamines with properties different from those of currently available drugs are nearing licensure. Named terfenidine and astemizole, they are almost exclusively H1-antagonists, lacking anticholinergic and sympathetic activity. They fail to penetrate the central nervous system and lack sedative effects. They are long-acting and require less frequent doses. Thus they allow sustained antihistaminic action without the usual side effects.